Quick Answer
Atea Pharmaceuticals, Inc. reported R&D Expense of $148.02 million for fiscal year 2025.
Atea Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $148.02M | +2.7% |
| 2024 | $144.10M | +26.1% |
| 2023 | $114.24M | +39.4% |
| 2022 | $81.94M | -51.0% |
| 2021 | $167.21M | +339.7% |
| 2020 | $38.02M | +273.9% |
| 2019 | $10.17M | +52.4% |
| 2018 | $6.67M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $38.35M | +46.6% | +18.8% |
| June 30, 2025 | $32.27M | -7.0% | +9.1% |
| March 31, 2025 | $29.58M | -48.6% | +13.1% |
| September 30, 2024 | $26.16M | -7.2% | -24.6% |
| June 30, 2024 | $34.70M | +57.3% | -39.7% |
| March 31, 2024 | $57.58M | +98.8% | +104.3% |
| September 30, 2023 | $28.18M | +474.5% | +27.7% |
| June 30, 2023 | $22.06M | +11.1% | -23.8% |
- Atea Pharmaceuticals, Inc. showed an increase of +2.7% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Atea Pharmaceuticals, Inc.’s r&d expense has grown by 2117.6% (from $6.67 million to $148.02 million).
- The most recent figure is from Atea Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: